Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyruvate dehydrogenase complex, E3-binding protein subunit (PDHX) is a structural component of the mitochondrial pyruvate dehydrogenase complex, essential in cellular respiration. PDHX encodes E3 binding protein, which tethers the E3 (dihydrolipoamide dehydrogenase) enzyme to the E2 core, ensuring proper assembly and function of the PDH complex. The PDH complex catalyzes the conversion of pyruvate to acetyl-CoA, linking glycolysis to the citric acid cycle and ATP production. Mutations in PDHX can cause pyruvate dehydrogenase deficiency, leading to lactic acidosis and severe neurological problems, primarily manifesting in infancy or early childhood. PDHX is also a minor autoantigen in primary biliary cholangitis, contributing to autoimmune destruction of bile duct epithelial cells and subsequent liver dysfunction[1][2][3][6].
Drugs may target the pyruvate dehydrogenase complex by activating residual enzymatic activity, reducing pyruvate accumulation, or managing lactic acidosis; not directly targeting PDHX but acting downstream or via cofactors[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyruvate dehydrogenase complex, E3-binding protein subunit (PDHX).